Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line cetuximab plus chemotherapy in RAS-converted metastatic colorectal cancer
2019-001328-36Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal adenocarcinoma and colorectal cancer (CRC), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Overall response rate. Started May 2021; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-001328-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001328-36.